Mabvax Therapeutics (MBVX) Stock Price, News & Analysis

Company Overview

MabVax Therapeutics Holdings, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Its lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials. The company's product candidates include MVT-5873, a therapeutic antibody that is in Phase I clinical trial for patients with advanced or metastatic adenocarcinoma of the pancreas (PDAC) and other CA19-9 positive malignancies; and MVT-2163, an immuno-positron emission tomography (PET) imaging agent, which is in Phase I clinical trial designed to evaluate a next generation diagnostic PET imaging agent in patients with PDAC or other CA19-9 positive malignancies. Its product candidates also comprise MVT-1075, a radioimmunotherapy agent that combines the company's HuMab-5B1 antibody with the radiopharmaceutical (177) Lutetium to treat pancreatic cancer. The company has various research agreements and collaborations with Memorial Sloan Kettering Cancer Center; a licensing agreement with Life Technologies Corporation; a research collaboration agreement with Rockefeller University's Laboratory of Molecular Genetics and Immunology; and a development and manufacturing services agreement with Patheon. MabVax Therapeutics Holdings, Inc. was founded in 2006 and is based in San Diego, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.01 to $1.15
• 52-Week Range: N/A
• Volume: 1,333 shs
• Average Volume: 31,620 shs
• Market Capitalization: $213 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MBVX Stock Analysis - Frequently Asked Questions

How were Mabvax Therapeutics' earnings last quarter?

Mabvax Therapeutics Holdings Inc (NASDAQ:MBVX) issued its quarterly earnings results on Tuesday, November, 7th. The company reported ($1.62) EPS for the quarter.

When did Mabvax Therapeutics' stock split?

Mabvax Therapeutics's stock reverse split before market open on Friday, February 16th 2018.The 1-3 reverse split was announced on Thursday, February 15th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 15th 2018. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

What other stocks do shareholders of Mabvax Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mabvax Therapeutics investors own include Immunomedics (IMMU), GW Pharmaceuticals (GWPH), Athersys (ATHX), Dollar General (DG), Bristol Myers Squibb (BMY), Gilead Sciences (GILD) and Zynerba Pharmaceuticals (ZYNE).

Company Calendar

• Last Earnings: 11/07/2017
• Today: 7/13/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MBVX
• Previous Symbol: OTCMKTS:TELKD
• CIK: 1109196
• Web: www.mabvax.com
• Phone: 858-259-9405
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 9,255,000
• Free Float: N/A
• Market Cap: $213 thousand
• Optionable: Not Optionable
• Beta: N/A